Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the same period last year. The growth was primarily driven by $11 million in net sales of TONMYA, the company’s recently approved treatment for fibromyalgia. During the quarter, TONMYA recorded 12,592 total prescriptions, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%.
The strong commercial performance underscores the market’s acceptance of TONMYA as the first new treatment for fibromyalgia in over 15 years. Coverage for TONMYA currently extends to approximately 136 million lives across commercial, managed Medicare, and Medicaid channels, and is expected to reach about 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. This expanded coverage is likely to further boost prescription volumes and revenue in the coming quarters.
Beyond its commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, subject to final FDA review and agreement on the protocol. These programs highlight Tonix’s commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology.
Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as Tonix continues to commercialize TONMYA and advance its pipeline.
The company’s CNS portfolio also includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare disease. In immunology, Tonix is developing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These investigational drugs and biologics have not yet been approved for any indication.
Tonix’s recent performance reflects a successful transition to a commercial-stage biotechnology company. The robust sales of TONMYA, coupled with pipeline progress, position the company for sustained growth in the CNS and immunology markets. As coverage expands and clinical trials advance, Tonix could become a significant player in addressing chronic pain and other neurological conditions.
For more information, visit the company’s newsroom at https://nnw.fm/TNXP.
